研究员

研究方向：

重大呼吸系统感染和肺损伤

研究工作：

1、病毒感染免疫保护与致病机制研究；

2、研发抗病毒感染的新型预防性疫苗平台和免疫治疗新型药物；

3、研发病毒相关肿瘤的免疫治疗抗体和大分子药物。

科研项目：

1、新型新冠融合蛋白疫苗：广州实验室应急攻关项目（800万元，2021.01–2022.12）主持

2、基于体液免疫的慢性乙型肝炎临床治疗转归精准预测及功能性治愈新策略（国家科技重大专项课题，271万元，2018.01-2020.12） 子课题负责人

代表性学术论文：

1、Chao-Yang Meng, Shiyu Sun, Yong Liang, Hairong Xu, Chao Zhang, Min Zhang, Fu-Sheng Wang, Yang-Xin Fu*, Hua Peng*. Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. Gut. 2023 Aug;72(8):1544-1554.

2、Shen J, Zou Z, Guo J, Cai Y, Xue D, Liang Y, Wang W, Peng H*, Fu YX*. An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery. J Exp Med. 2022 Dec 5;219(12): e20220745.

3、Yifan Lin#, Jing Sun#, Xuezhi Cao#, Xiuye Wang, Xi Chen, Hairong Xu, Jincun Zhao*, Yang-Xin Fu* and Hua Peng*. Non-adjuvanted interferon-armed RBD protein nasal drops protect airway infection from SARS-CoV-2. Cell Discov. 2022; 8: 43.

4、Diyuan Xue#, Benjamin Moon#, Jing Liao, Jingya Guo, Zhuangzhi Zou, Yanfei Han, Shuaishuai Cao, Yang Wang, Yang-Xin Fu*, Hua Peng*. A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors. Science Immunology, 2022 Jan 7;7(67):eabi68

5、Sunshiyu Sun#, Yueqi Cai#, Tian-Zhang Song#, Yang Pu#, Lin Cheng, Hairong Xu, ChaoyangMeng, Yifan Lin, Haibin Huang, Fang Zhao, Jing Sun, Silin Zhang, Yu Gao, Jian-Bao Han, Xiao-Li Feng, Dan-Dan Yu, Haidong Tang, Jincun Zhao, Zheng Zhang, Jiaming Yang, Zhenxiang Hu, Yang-Xin Fu*, Yong-Tang Zheng*, Hua Peng*. Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. Cell Res. 2021 Sep;31(9):1011-1023.

6、Jingya Guo, Yong Liang, Diyuan Xue, Jiao Shen, Yueqi Cai, Jiankun Zhu, Yang-Xin Fu*, Hua Peng*. Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity. Cell Res. 2021 Nov;31(11):1190-1198.

7、Sisi Deng, Zhichen Sun, Jian Qiao, Yong Liang, Longchao Liu, Chunbo Dong, Aijun Shen, Yang Wang, Hong Tang, Yang-Xin Fu, and Hua Peng. Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells. JCI Insight. 2020;5(7):e132000.

8、Yong Liang, Haidong Tang, Jingya Guo, Xiangyan Qiu, Zhenhua Ren, Yingjie Bian, Zhichen Sun, Haidong Dong, Hua Peng*, Yang-Xin Fu*. Targeting type I interferon tumor entry by anti-PD-L1 creates feedforward antitumor responses to overcome innate and adaptive resistance. Nat Commun. 2018 Nov 2;9(1):4586.

9、Zhichen Sun, Zhenhua Ren, Kaiting Yang, Shuaishuai Cao, Sisi Deng, Lily Xu, Yong Liang, Jingya Guo, Yingjie Bian, Hairong Xu, Jiyun Shi, Fan Wang, Yang-Xin Fu*, and Hua Peng*. A next generation tumor-targeting IL-2 preferentially promotes tumor infiltrating CD8+ T cells response and effective tumor control. Nat Commun. 2019 Aug 28;10(1):3874.

10、Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, Liu X, Harrington SM, Guo J, Xin Y, Xiong Y, Nham K, Silvers W, Hao G, Sun X, Chen M, Hannan R, Qiao J, Dong H*, Peng H*, Fu YX. *, PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Invest. 2018 Feb 1;128 (2):580-588.

联系方式：

Email: peng_hua@gzlab.ac.cn